Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients

Phase 2

Completed

Brief Summary: The purpose of this study is to evaluate the use of olanzapine for the treatment of cancer patients with chronic nausea and/or vomiting unrelated to chemotherapy or radiation in a randomized placebo-controlled pilot trial.

Detailed Description: Patients with advanced cancer experience a variety of physical and psychosocial symptoms that significantly affect the patients' quality of life. Chronic nausea is a particularly distressing symptom present in \>60% of patients with advanced cancer. A number of palliative care studies have evaluated treatments of nausea with limited success. Olanzapine with its unique formulation and decreased drug interactions compared to many other drugs appears to be a reasonable candidate for further evaluation. Olanzapine has significant potential for use in the prevention and treatment of nausea in a palliative care setting with a once-daily dosing.

Recruitment & Eligibility

Inclusion Criteria

Be at least 18 years of age
Have histologically or cytologically-confirmed malignant disease in an advanced incurable stage
Have not received chemotherapy or radiation for >14 days (advanced cancer patients receiving hormonal therapy or targeted therapy that does not come with a recommendation for prophylactic anti-emetic therapy are eligible)
Have chronic nausea that has been present for at least one week (worst daily score >3, 0-10 visual analogue scale) or vomiting at least five times over past one week
Have serum creatinine < 2.0 mg/dl and serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) < 3 times upper limits of normal ≤120 days prior to registration
Absolute neutrophil count (ANC) >1500 mm3 <120 days prior to registration
Women of childbearing potential must consent to use adequate contraception throughout protocol therapy; females of childbearing potential must have a negative urine pregnancy test <7 days prior to registration.

Exclusion Criteria

Not be receiving treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for less than or equal to 30 days prior to registration or planned during protocol therapy (patients may have received prochlorperazine and other phenothiazines as prior anti-emetic therapy)
Not have concurrent use of ethyol
Not have severe cognitive compromise
History of central nervous system (CNS) disease (e.g. brain metastases, seizure disorder)
Concurrent use of amifostine, concurrent abdominal radiotherapy; concurrent use of quinolone antibiotic therapy
Chronic alcoholism (as determined by the investigator)
Known hypersensitivity to olanzapine
Known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months
History of uncontrolled diabetes mellitus (stable insulin dose and/or stable oral hypoglycemic agent permitted)
Planned chemotherapy or radiation during the 7 days following study initiation.

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Patients will receive a placebo orally for 1 to 7 days daily.
Olanzapine	Olanzapine	Patients will receive 5 mg olanzapine orally for 1 to 7 days daily.

Primary Outcome Measures

Name	Time	Method
Mean Nausea Scores	Nausea score from the Visual Analogue Scale will be recorded each day daily for 7 days. An average value calculated will be reported for the 7 day period.	Daily nausea scores (the primary objective) on day 1 to 7 of treatment for each patient from the Olanzapine and Placebo group will be measured using the Visual Analogue Scale rankings from 0-10 where 0 is no nausea and 10 is the maximum nausea experienced by a patient. A Visual Analogue Scale is a psychometric response scale which can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that can't be directly measured. Patients will be asked to record the average nausea score for each day in a diary and a study nurse will call the patient at the same time each day to remind the patient to record the nausea score and to inquire about any toxicities. The difference in the nausea scores for the patients in each group (Olanzapine and Placebo) will be compared.

Secondary Outcome Measures

Name	Time	Method
Number of Emetic Episodes	Number of emetic episodes for each patient on each day of the seven day treatment.	The number of emetic episodes (a secondary outcome) by each patient in each group, Olanzapine \& Placebo, on each day of treatment will be recorded by each patient on each day of treatment in a diary. A study nurse will contact each patient at the same time of each day of the study to ask the patient to record the number of emetic episodes and report any toxicities.The number of emetic episodes for the patients in each Group for each day of the treatment will be compared.
Number of Treatment-related Adverse Events as Assessed by CTCAE v4.0".	Daily assessment for 7 days for each patient in Olanzapine & Placebo Groups.	Adverse events will be measured by patient-reported outcomes questionnaires and the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A study nurse will contact each patient each day of the seven days of treatment to inquire about any toxicities, specifically sedation and appetite. Sedation and appetite will be reported by the patient in each Group on a Visual Analogue Scale of 0 to 10 with 0 being no sedation or no appetite to 10 indicating maximum sedation or maximum appetite.

Locations (5): Washington University School of Medicine
🇺🇸
Saint Louis, Missouri, United States
Hospital Sisters Health System (HSHS) St. Vincent Hospital
🇺🇸
Green Bay, Wisconsin, United States
University of Alabama at Birmingham
🇺🇸
Birmingham, Alabama, United States
Indiana University
🇺🇸
Indianapolis, Indiana, United States
Mayo Clinic
🇺🇸
Rochester, Minnesota, United States